The global skeletal dysplasia market is anticipated to grow with a modest growth rate during the forecast period. The skeletal dysplasia disorder is a heterogeneous group of more than 350 disorders found in both adults and children. Skeletal dysplasia is frequently associated with orthopedic complications and varying degrees of dwarfism or short stature.
It is a rare disease and is observed in 2.4 per 10,000 births (as per the Johns Hopkins University). Skeletal dysplasia disorder also affects significant number of young children. The severity of the disorder is very high in children as along with the various orthopedic problems they also suffer from a frequent chest infection, hearing, and breathing difficulty. The growth of the skeletal dysplasia market is attributed to the advancements in the understanding of the pathophysiology of skeletal dysplasia that is propelling the efforts in treatment strategies. Additionally, emerging new advanced drug therapy for the treatment of skeletal dysplasia will also fuel the skeletal dysplasia market industry.
A Full Report of Global Skeletal Dysplasia Market is Available at: https://www.omrglobal.com/industry-reports/skeletal-dysplasia-market
Global Skeletal Dysplasia Market – Segmentation
By Type
• Achondroplasia
• Thanatophoric dysplasia
• Hypochondroplasia
• Others
By Treatment
• Medications
• Therapy
• Others (Surgery)
By Company Profiles
• Alexion Pharmaceuticals, Inc.
• Amgen Inc.
• Ascendis Pharma A/S
• BioMarin Pharmaceutical Inc.
• Invitae Corp.
• Ipsen Pharma
• Merck KGaA
• Novartis AG
• Novo Nordisk A/S
• Pfizer Inc.
• Regeneron Pharmaceuticals Inc.
• Thermo Fisher Scientific Inc
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
